Pain Management and Breast Cancer Diagnosis

Introduction to Breast Cancer Diagnosis

The American College of Radiology recommends either ultrasound or diagnostic mammography/tomosynthesis as initial imaging modalities for breast cancer diagnosis, with a combined approach if initial imaging is inconclusive 1, 2
The American Society of Clinical Oncology and the European Society for Medical Oncology support the use of anti-inflammatory drugs for pain control in cancer patients, including those with breast cancer 3, 4

Ultrasound is the preferred first imaging modality, especially in younger women with palpable masses, with a sensitivity of 95.7% compared to 60.9% for mammography 1, 2
The following table summarizes the recommendations for ultrasound findings:

Ultrasound Finding	Recommendation
Simple cyst	No further workup needed [1]
Solid mass with benign features	Short-interval follow-up if mammography and clinical examination also suggest benign etiology [1]
Biopsy warranted	If the mass is new, increasing in size, or if the patient has high-risk factors [1]

Core needle biopsy (CNB) is preferred over fine needle aspiration (FNA) for breast lesions, ensuring concordance between pathology report and imaging findings 5, 6
Radiologically guided core biopsy is recommended for impalpable lesions, and histological diagnosis should be compared with diagnostic hypotheses from imaging 7

The standard histological report should include size of malignant lesion(s) in mm, histological type and grade, percentage of any ductal carcinoma in situ, presence of peritumoral vascular invasion, status of surgical margins, as recommended by the British Journal of Cancer guidelines 7
The pathological assessment should include histological type, grade, estrogen receptor (ER) and progesterone receptor (PgR) status, HER2 status, and Ki67 when appropriate, according to the European Society for Medical Oncology 8, 9

For a benign mass concordant with imaging, physical examination at 6 or 12 months, with or without ultrasound or mammogram, and follow-up for 1-2 years to ensure stability, after which routine screening can be resumed if the lesion remains stable 6
Surgical excision is recommended for indeterminate lesions, benign lesions not concordant with imaging, atypical ductal hyperplasia (ADH), mucin-producing lesions, potential phyllodes tumor, papillary lesions, and radial scars 6
Diagnosis of ductal carcinoma in situ, lobular carcinoma in situ, and atypical hyperplasia from needle biopsy should always be confirmed with surgical excision, according to the British Journal of Cancer guidelines 7
Follow-up with mammography every 6-12 months for 1-2 years, and after 1-2 years of stability, return to routine screening is suggested 5, 2
MRI is not routinely recommended but should be considered in specific situations, such as familial breast cancer associated with BRCA mutations, breast implants, lobular cancers, before neoadjuvant chemotherapy, when findings of conventional imaging are inconclusive, or suspicion of multifocality/multicentricity 8

For higher-risk disease, additional staging workup should include complete blood count, liver and renal function tests, alkaline phosphatase, and calcium, as recommended by the European Society for Medical Oncology 8, 9
Assessment for distant metastases is only recommended in stage IIb and higher disease 9